Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 16:04:54 ON 29 MAR 2008
FILE 'CAPLUS' ENTERED AT 16:04:54 ON 29 MAR 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	18.75	578.62
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-5.60

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	19.23	579.10
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.40	-5.60

FILE 'REGISTRY' ENTERED AT 16:05:13 ON 29 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAR 2008 HIGHEST RN 1010855-43-2
DICTIONARY FILE UPDATES: 28 MAR 2008 HIGHEST RN 1010855-43-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10781305resptoRCE.str

L12   STRUCTURE UPLOADED

=> d l12
L12 HAS NO ANSWERS
L12   STR



G1 O,NH

G2 H,Cl,Br,F,I

Structure attributes must be viewed using STN Express query preparation.

=> s l12
SAMPLE SEARCH INITIATED 16:05:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 229 TO 851
PROJECTED ANSWERS: 0 TO 0

L13 0 SEA SSS SAM L12

=> s l12 full
FULL SEARCH INITIATED 16:05:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 477 TO ITERATE

100.0% PROCESSED 477 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

L14 16 SEA SSS FUL L12

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 757.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -5.60

FILE 'CAPLUS' ENTERED AT 16:05:41 ON 29 MAR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 29 Mar 2008 VOL 148 ISS 14
FILE LAST UPDATED: 28 Mar 2008 (20080328/ED)

=> s l14
L15 6 L14

=> d bib abs hitstr 1-6 l15

L15 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:966427 CAPLUS
DN 143:318373
TI 4'-Ethynylstavudine (4'-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants
AU Tanaka, Hiromichi; Haraguchi, Kazuhiro; Kumamoto, Hiroki; Baba, Masanori; Cheng, Yung-Chi
CS School of Pharmaceutical Sciences, Showa University, Tokyo, Japan
SO Antiviral Chemistry & Chemotherapy (2005), 16(4), 217-221
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English
AB A nucleoside analog 4'-ethynylstavudine (4'-Ed4T) was recently synthesized during chemical studies directed towards the development of a new route to 4'-carbon-substituted nucleosides. This compound was more anti-HIV-1 active than the parent compound stavudine (d4T) and much less toxic to various cells and also to mitochondrial DNA synthesis. It became apparent that 4'-Ed4T is a better substrate for human thymidine kinase than d4t, and very much more resistant to catabolism by thymidine phosphorylase. The study of 4'-Ed4T against various drug-resistant HIV-1 mutants has disclosed its unique activity profile.
IT 717913-90-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethynylstavudine has potent anti-HIV-1 activity with reduced toxicity and shows unique activity profile against drug-resistant mutants)
RN 717913-90-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-2,5-dihydro-5-(hydroxymethyl)-5-(2-propenyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:701799 CAPLUS
DN 141:225774
TI Preparation of 2',3'-dideoxy and 2',3'-didehydro nucleoside analogs as

prodrugs for treating viral infections, most notably HIV
IN Cheng, Yung-chi; Tanaka, Hiromichi; Baba, Masanori
PA USA
SO U.S. Pat. Appl. Publ., 45 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 2004167096	A1	20040826	US 2004-781305	20040218	my app
AU 2004260630	A1	20050210	AU 2004-260630	20040218	
CA 2514466	A1	20050210	CA 2004-2514466	20040218	
WO 2005011709	A1	20050210	WO 2004-US4713	20040218	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
BR 2004007374	A	20060110	BR 2004-7374	20040218	
EP 1653976	A1	20060510	EP 2004-775776	20040218	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1777432	A	20060524	CN 2004-80010529	20040218	
JP 2006528972	T	20061228	JP 2006-532288	20040218	
IN 2005KN01553	A	20061027	IN 2005-KN1553	20050805	
MX 2005PA08736	A	20051005	MX 2005-PA8736	20050817	
ZA 2005006630	A	20060628	ZA 2005-6630	20050818	
PRAI US 2003-448554P	P	20030219			
WO 2004-US4713	W	20040218			

OS CASREACT 141:225774; MARPAT 141:225774
GI





AB Nucleosides I, wherein B is nucleobase; Z is O or CH2; R is H, OH, halo, alkyl substituents; R1 can be H, Me, alkenyl, alkynyl; R2 is H, acyl, alkyl, ether, phosphoethers; and 2',3'-didehydro nucleosides II where Z is O; and R3 can alkyl, alkenyl, alkynyl, halo, hydroxy, were prepared as prodrugs and antiviral agents. Thus, the synthesized 2',3'-dideoxy and didehydro nucleoside analogs were tested as potential antiviral, anti-HIV and anti-infective prodrugs as independent agents, or in combination with other agents. Specifically, didehydro nucleoside III was prepared and tested in vitro as potent anti-HIV-1 agent (EC50 = 0.25 ± 0.14) and as well less toxic (ID50 >256) as D4T, therefor has the potential as a new anti-HIV drug.
IT 717913-90-1P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);

PREP (Preparation); USES (Uses)
(synthesis of 2',3'-dideoxy and didehydro nucleoside analog and their evaluation as antiviral, anti-HIV and anti-infective prodrugs)
RN 717913-90-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-2,5-dihydro-5-(hydroxymethyl)-5-(2-propenyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:374658 CAPLUS
DN 141:99075
TI Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity
AU Dutschman, Ginger E.; Grill, Susan P.; Gullen, Elizabeth A.; Haraguchi, Kazuhiro; Takeda, Shingo; Tanaka, Hiromichi; Baba, Masanori; Cheng, Yung-Chi
CS Department of Pharmacology, School of Medicine, Yale University, New Haven, CT, 06520, USA
SO Antimicrobial Agents and Chemotherapy (2004), 48(5), 1640-1646
CODEN: AMACCQ; ISSN: 0066-4804
PB American Society for Microbiology
DT Journal
LA English
AB The antiviral drug 2',3'-didehydro-3'-deoxythymidine (D4T; also know as stavudine and Zerit), which is used against human immunodeficiency virus (HIV), causes delayed toxicity (peripheral neuropathy) in long-term use. After examining a series of 2',3'-didehydro-3'-deoxy-4'-substituted thymidine (4'-substituted D4T) analogs, 4'-ethynyl D4T was found to have a fivefold better antiviral effect and to cause less cellular and mitochondrial toxicity than D4T. The antiviral activity of this compound can be reversed by dThd but not by dCyd. The compound acted synergistically with β-L-2',3'-deoxy-3'-thiacytidine (also known as lamivudine) and β-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (also known as elvucitabine) and additively with 2',3'-dideoxyinosine (also known as didanosine and Videx) and 3'-azido-3'-deoxythymidine (also known as Retrovir and zidovudine) against HIV. 4'-Ethynyl D4T is phosphorylated by purified human thymidine kinase 1 (TK-1) from CEM cells with a faster relative Vmax and a lower Km value than D4T. The efficiency of TK-1 in the phosphorylation of 4'-ethynyl D4T is fourfold better than that of D4T. While D4T is broken down by the catabolic enzyme thymidine phosphorylase, the level of breakdown of 4'-ethynyl D4T was below detection. Since 4'-ethynyl D4T has increased anti-HIV activity and decreased toxicity and interacts favorably with other currently used anti-HIV drugs, it should be considered for further development as an anti-HIV drug.
IT 717913-90-1, 4'-Allyl-2',3'-Didehydro-3'-deoxythymidine
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(4'-substituted stavudine analog with improved anti-HIV activity and decreased cytotoxicity)
RN 717913-90-1 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[(2R,5S)-2,5-dihydro-5-(hydroxymethyl)-5-(2-propenyl)-2-furanyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1996:183061 CAPLUS
DN 124:202920
TI Allylic Substitution of 3',4'-Unsaturated Nucleosides: Organosilicon-Based Stereoselective Access to 4'-C-Branched 2',3'-Didehydro-2',3'-dideoxyribonucleosides
AU Haraguchi, Kazuhiro; Tanaka, Hiromichi; Itoh, Yoshiharu; Yamaguchi, Kentaro; Miyasaka, Tadashi
CS School of Pharmaceutical Sciences, Showa University, Tokyo, 142, Japan
SO Journal of Organic Chemistry (1996), 61(3), 851-8
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 124:202920
GI



AB Reactions of organosilicon reagents (such as allyltrimethylsilane, silyl enol ethers, cyanotrimethylsilane) with 3',4'-unsatd. nucleosides, e.g. I (R = Ac, Bz, TBDPS), were investigated in the presence of a Lewis acid in CH2Cl2. In the cases of uracil and N4-acetylcytosine derivs., SnCl4 appeared to be suitable, whereas the use of EtAlCl2 was necessary for the hypoxanthine derivs. The main pathway of these reactions was found to be α-face-selective SN2' allylic substitution, irresp. of the configuration of 2'-O-acyl leaving group. As a result, a new stereoselective operation for C-C bonds formation leading to 4'-carbon-substituted 2',3'-didehydro-2',3'-dideoxyribonucleosides, e.g. II (R = Ac, Bz, TBDPS), has been disclosed for the first time. Stereochem. of these 4'-C-branched products can be assigned on the basis of 1H NMR spectroscopy in terms of the anisotropic shift of H-5 of the pyrimidine base (or H-8 of the hypoxanthine), which is caused by the 5'-O-(tert-butyldiphenylsilyl) protecting group.
IT 174275-93-5P 174391-02-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective allylic substitution of unsatd. nucleosides in preparation of branched didehydrodideoxyribonucleosides)
RN 174275-93-5 CAPLUS
CN Cytidine, N-acetyl-2',3'-didehydro-2',3'-dideoxy-4'-C-2-propenyl-, 5'-acetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174391-02-7 CAPLUS
CN Acetamide, N-[1-[5-[(acetyloxy)methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 142468-65-3P 142468-66-4P 142468-69-7P
142468-70-0P 142560-91-6P 142560-93-8P
142562-94-9P 142562-05-8P 174275-94-6P
174391-03-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective allylic substitution of unsatd. nucleosides in preparation of branched didehydrodideoxyribonucleosides)
RN 142468-65-3 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-66-4 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-69-7 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-70-0 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-91-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-93-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-oxopropyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-94-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-oxo-2-phenylethyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142562-05-8 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)dimethylsilyl]-4'-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174275-94-6 CAPLUS
CN Cytidine, N-acetyl-2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-C-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 174391-03-8 CAPLUS
CN Acetamide, N-[1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-1,2-dihydro-2-oxo-4-pyrimidinyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1994:164819 CAPLUS
DN 120:164819
TI 4'-Carbon-substituted pyrimidine nucleosides as pharmaceuticals and their preparation
IN Haraguchi, Kazuhiro; Tanaka, Hiromichi; Myasaka, Sada
PA Yamasa Shoyu Kk, Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05230058	A	19930907	JP 1992-72915	19920224
PRAI	JP 1992-72915		19920224		
OS	CASREACT 120:164819; MARPAT 120:164819				
GI					



I II

AB The title compds. I [R1 = H, halo, lower alkyl; (X1, X2) = (R2, CH2OR3), (CH2OR3, R2); R2 = allyl, 2-alkylallyl, cycloalkanon-2-yl, R4CH2, cyano; R3 = H, protective group; R4 = acyl], which show antiviral or antitumor activity (no data), are prepared by treating nucleosides II (R1 = same as I; R5 = acyl; R6 = protective group) with organosilicon compds. in presence of Lewis acids. II (R1 = H, R5 = Ac, R6 = SiPh2CMe3) (preparation given) was treated with allyltrimethylsilane and SnCl4 in CH2Cl2 at ≤-70° for 7 h to give 74% I (R1 = H, X1 = CH2OSiPh2CMe3, X2 = allyl) and 5% I (R1 = H, X1 = allyl, X2 = CH2OSiPh2CMe3).

IT 142468-65-3P 142468-68-6P 142468-69-7P
142468-70-0P 142560-91-6P 142560-92-7P
142560-93-8P 142560-94-9P 153298-99-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pharmaceutical)

RN 142468-65-3 CAPLUS

CN Uridine, 2',3'-dideohydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-68-6 CAPLUS

CN Uridine, 2',3'-dideohydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 142468-69-7 CAPLUS

CN Uridine, 2',3'-dideohydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-70-0 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-91-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-92-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-methyl-2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-93-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-oxopropyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-94-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]m
ethyl]-2,5-dihydro-5-(2-oxo-2-phenylethyl)-2-furanyl]-, (2R-trans)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 153298-99-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[2,5-dihydro-5-(hydroxymethyl)-5-(2-
propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1992:470218 CAPLUS
DN 117:70218
TI Stereoselective synthesis of 4'-C-branched 2',3'-didehydro-2',3'-dideoxy
nucleosides based on tin tetrachloride-promoted allylic rearrangement
AU Haraguchi, Kazuhiro; Tanaka, Hiromichi; Itoh, Yoshiharu; Saito, Shigeru;
Miyasaka, Tadashi
CS Sch. Pharm. Sci., Showa Univ., Tokyo, 142, Japan
SO Tetrahedron Letters (1992), 33(20), 2841-4
CODEN: TELEAY; ISSN: 0040-4039
DT Journal
LA English
OS CASREACT 117:70218
GI



I

AB Based on SnCl4-promoted allylic rearrangement between a 3',4'-unsatd. uracil nucleoside and organosilicon reagents, stereoselective introduction of carbon functionalities to the 4'-position has been accomplished, disclosing a new entry for a series of 4'-C-branched nucleosides, e.g. I (R = MeCCPh2Si, R1 = CH2CH:CH2, CH2CMe:CH2, CN, phenacyl), of biol. interest.

IT 142468-65-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and desilylation of)

RN 142468-65-3 CAPLUS

CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 142468-66-4P 142468-68-6P 142468-69-7P
142468-70-0P 142560-91-6P 142560-92-7P
142560-93-8P 142560-94-9P 142562-05-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 142468-66-4 CAPLUS

CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-68-6 CAPLUS

CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-methyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 142468-69-7 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142468-70-0 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)diphenylsilyl]-4'-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-91-6 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-92-7 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-methyl-2-propenyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-93-8 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-oxopropyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142560-94-9 CAPLUS
CN 2,4(1H,3H)-Pyrimidinedione, 1-[5-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]methyl]-2,5-dihydro-5-(2-oxo-2-phenylethyl)-2-furanyl]-, (2R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142562-05-8 CAPLUS
CN Uridine, 2',3'-didehydro-2',3'-dideoxy-5'-O-[(1,1-dimethylethyl)dimethylsilyl]-4'-(2-propenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.